Barinthus Biotherapeutics (NASDAQ:BRNS) Shares Down 15.5% - Here's Why

Key Points

• Barinthus Biotherapeutics shares fell 15.5% to $1.25 after closing at $1.48, with trading volume significantly increasing to 832,679 shares, compared to the average of 156,556 shares.
• The company reported a significant loss of ($0.52) earnings per share in its recent quarterly earnings, missing analysts' estimates by $0.23.
• HighTower Advisors LLC recently acquired a new stake in Barinthus Biotherapeutics, purchasing 37,450 shares valued at around $36,000, which reflects institutional investors owning 25.20% of the company.

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Get Free Report) traded down 15.5% on Tuesday . The stock traded as low as $1.06 and last traded at $1.25. 832,679 shares traded hands during mid-day trading, an increase of 432% from the average session volume of 156,556 shares. The stock had previously closed at $1.48.

Barinthus Biotherapeutics Stock Down 15.5%

The company has a market cap of $50.90 million, a price-to-earnings ratio of -0.72 and a beta of -0.75. The company has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.05.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.23). On average, research analysts predict that Barinthus Biotherapeutics PLC Sponsored ADR will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC purchased a new position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 37,450 shares of the company's stock, valued at approximately $36,000. HighTower Advisors LLC owned 0.09% of Barinthus Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 25.20% of the company's stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.